MONDAY, SEPTEMBER 26, 2016

CEL-SCI and NIAID collaborate on bird flu study

The National Institute of Allergy and Infectious Diseases and scientists from CEL-SCI Corporation recently submitted an efficacy study for publication related to the use of activated dendritic cells to treat H1N1 bird flu.

The collaborative study involved the use of ligand epitope antigen presentation system H1N1-activated dendritic cells to treat H1N1 bird flu. The study addresses how the specific and selectively directed activity induced by the LEAPS-activated DCs could be used to treat and mitigate pandemic flu.

LEAPS technology is a novel T-cell modulation platform technology that the Vienna, Va.-based CEL-SCI uses to design and develop non-recombinant, proprietary immunogens. The technology combines a small peptide from a disease-related highly conserved protein molecule with a small peptide that activates the immune system.

The study could have applications to the new H7N9 bird flu strain currently detected in China. A review of information by CEL-SCI suggests the regions used in the H1N1 treatment study appear to be similar to the regions found in H7N9. Not enough information is available for any definitive statements to be made about the applicability of LEAPS for H7N9.

The LEAPS-H1N1-DC treatment targets non-changing regions of the H1N1 pandemic flu, H5N1 avian flu and the Spanish Flu. Scientists with CEL-SCI are concerned about the emergence of a new and more virulent hybrid virus that could combine Spanish Flu, H5N1 and H1N1.